GSK PLC SP. ADR/2 NEW (F:GS70) — Market Cap & Net Worth
Market Cap & Net Worth: GSK PLC SP. ADR/2 NEW (GS70)
GSK PLC SP. ADR/2 NEW (F:GS70) has a market capitalization of $101.34 Billion (€86.68 Billion) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #248 globally and #49 in its home market, demonstrating a -3.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GSK PLC SP. ADR/2 NEW's stock price €47.20 by its total outstanding shares 2006642158 (2.01 Billion). Review GS70 total debt and obligations to assess the company's total debt and financial obligations.
GSK PLC SP. ADR/2 NEW Market Cap History: 2015 to 2026
GSK PLC SP. ADR/2 NEW's market capitalization history from 2015 to 2026. Data shows growth from $51.20 Billion to $106.98 Billion (7.94% CAGR).
GSK PLC SP. ADR/2 NEW Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GSK PLC SP. ADR/2 NEW's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.02x
GSK PLC SP. ADR/2 NEW's market cap is 3.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.24x
GSK PLC SP. ADR/2 NEW's market cap is 17.24 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $82.99 Billion | $24.70 Billion | $4.38 Billion | 3.36x | 18.93x |
| 2022 | $70.62 Billion | $29.32 Billion | $14.96 Billion | 2.41x | 4.72x |
| 2023 | $75.11 Billion | $30.33 Billion | $4.93 Billion | 2.48x | 15.24x |
| 2024 | $76.48 Billion | $31.38 Billion | $2.58 Billion | 2.44x | 29.70x |
| 2025 | $98.53 Billion | $32.67 Billion | $5.72 Billion | 3.02x | 17.24x |
Competitor Companies of GS70 by Market Capitalization
Companies near GSK PLC SP. ADR/2 NEW in the global market cap rankings as of June 19, 2026.
Key companies related to GSK PLC SP. ADR/2 NEW by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #26 globally with a market cap of $564.26 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #41 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1112.00 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #26 | Johnson & Johnson | NYSE:JNJ | $564.26 Billion | $234.20 |
| #41 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $221.23 |
GSK PLC SP. ADR/2 NEW Historical Marketcap From 2015 to 2026
Between 2015 and today, GSK PLC SP. ADR/2 NEW's market cap moved from $51.20 Billion to $ 106.98 Billion, with a yearly change of 7.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €106.98 Billion | +8.57% |
| 2025 | €98.53 Billion | +28.83% |
| 2024 | €76.48 Billion | +1.82% |
| 2023 | €75.11 Billion | +6.36% |
| 2022 | €70.62 Billion | -14.90% |
| 2021 | €82.99 Billion | +37.10% |
| 2020 | €60.53 Billion | -20.23% |
| 2019 | €75.89 Billion | +38.39% |
| 2018 | €54.84 Billion | +19.42% |
| 2017 | €45.92 Billion | -14.67% |
| 2016 | €53.81 Billion | +5.11% |
| 2015 | €51.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GSK PLC SP. ADR/2 NEW was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $101.34 Billion USD |
| MoneyControl | $101.34 Billion USD |
| MarketWatch | $101.34 Billion USD |
| marketcap.company | $101.34 Billion USD |
| Reuters | $101.34 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more